SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Martek Biosciences---- future biotech cash cow! -- Ignore unavailable to you. Want to Upgrade?

To: MOLLYSUE who wrote (183)5/10/1999 10:10:00 PM
From: JG  Respond to of 258
 
That would be lovely. The FDA has sat on this for over two years, mainly because ABBOTT LABS took the unprecedented step of actively opposing DHA and lobbying intensely against it.

The only alternative theory for the stock jump would be a buyout (J&J?). I'm sure we'll here soon.



To: MOLLYSUE who wrote (183)5/11/1999 12:17:00 AM
From: Robert Douglas  Read Replies (1) | Respond to of 258
 
The post you mention on Yahoo lists Mead Johnson and Carnation. If these companies are planning on putting Formulaid in pre-term only, it is a good step but not the ultimate one we want. What we need is for general use in full-term infant formulas. Following that we need these formulas to start taking market share from the Abbotts of the world forcing them to add it as well. Am I dreaming?

-Robert


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News